Published in Clin Infect Dis on July 15, 2008
The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin. Aliment Pharmacol Ther (2011) 0.91
Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitis. Mediterr J Hematol Infect Dis (2010) 0.88
Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med (2011) 4.68
Control of mammalian circadian rhythm by CKIepsilon-regulated proteasome-mediated PER2 degradation. Mol Cell Biol (2005) 3.03
Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda. BMJ (2009) 1.98
Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed. AIDS (2007) 1.85
Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry (2008) 1.61
Transdermal fentanyl improves pain control and functionality in patients with osteoarthritis: an open-label Canadian trial. Clin Rheumatol (2007) 1.47
Male gender predicts mortality in a large cohort of patients receiving antiretroviral therapy in Uganda. J Int AIDS Soc (2011) 1.46
Bipolar patients can safely and successfully receive interferon-based hepatitis C antiviral treatment. Eur J Gastroenterol Hepatol (2012) 1.43
Clinical and immunological outcomes of a national paediatric cohort receiving combination antiretroviral therapy in Uganda. AIDS (2008) 1.35
Suboptimal initiation of dialysis with and without early referral to a nephrologist. Nephrol Dial Transplant (2011) 1.26
Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine (2004) 1.23
Association of aging and survival in a large HIV-infected cohort on antiretroviral therapy. AIDS (2011) 1.16
Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data. Liver Int (2011) 1.06
Development and validation of the HIV Medication Readiness Scale. Assessment (2007) 0.97
Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis (2012) 0.97
Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study. Drugs Aging (2009) 0.95
Inflammation and repair in viral hepatitis C. Dig Dis Sci (2008) 0.94
Tuberculosis mortality in HIV-infected individuals: a cross-national systematic assessment. Clin Epidemiol (2011) 0.93
Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis. Clin Exp Gastroenterol (2012) 0.93
Bed utilization of patients with methicillin-resistant Staphylococcus aureus in a Canadian tertiary-care center. Infect Control Hosp Epidemiol (2002) 0.89
Increasing public awareness about hepatitis C: development and validation of the brief hepatitis C knowledge scale. Scand J Caring Sci (2009) 0.89
Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus. Can J Gastroenterol (2008) 0.88
Gender differences in clinical, immunological, and virological outcomes in highly active antiretroviral-treated HIV-HCV coinfected patients. Patient Prefer Adherence (2010) 0.85
Cohort profile: the TASO-CAN Cohort Collaboration. Int J Epidemiol (2011) 0.85
Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma. Am J Clin Oncol (2010) 0.85
The STARRT trial: a cost comparison of optimal vs sub-optimal initiation of dialysis in Canada. J Med Econ (2011) 0.80
Interpreting discordant indirect and multiple treatment comparison meta-analyses: an evaluation of direct acting antivirals for chronic hepatitis C infection. Clin Epidemiol (2013) 0.80
Influence of female sex on hepatitis C virus infection progression and treatment outcomes. Eur J Gastroenterol Hepatol (2016) 0.79
Transient elastography, APRI, and ultrasound have minimal utility in chronic low-replicative hepatitis B infection. Eur J Gastroenterol Hepatol (2014) 0.79
Parasitic disease screening among HIV patients from endemic countries in a Toronto clinic. Can J Infect Dis Med Microbiol (2012) 0.79
Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. Invest New Drugs (2006) 0.77
Does the storage age of transfused blood affect outcome in burn patients? J Burn Care Res (2014) 0.76
Hollow-fiber assay for ligand-mediated cell adhesion. Cytometry A (2004) 0.76
Increased nitric oxide concentrations in the small airway of older normal subjects. Chest (2010) 0.76
Analytical and biological variables influencing quantitative hepatitis C virus (HCV) measurement in HIV-HCV coinfection. Can J Gastroenterol (2006) 0.75
De-"Liver"-ing HIV/hepatitis C virus-coinfected patients from antiretroviral hepatotoxicity. J Infect Dis (2007) 0.75
Treatment, care and support for people co-infected with HIV and hepatitis C: a scoping review. Open Med (2009) 0.75
Is pre-treatment liver biopsy necessary for all hepatitis C genotypes? Ann Hepatol (2011) 0.75
Successes in the HIV epidemic response in Africa: maintaining momentum in uncertain times. Int J Infect Dis (2010) 0.75
Liver enzyme normalization predicts success of Hepatitis C oral direct-acting antiviral treatment. Clin Invest Med (2017) 0.75
Hepatitis C antiviral treatment outcomes are comparable between clinical trial participants and recipients of standard-of-care therapy: an analysis of trial effect. Eur J Gastroenterol Hepatol (2013) 0.75
Fibroblast Growth Factor 23 Predicts Mortality and End-Stage Renal Disease in a Canadian Asian Population with Chronic Kidney Disease. Nephron (2017) 0.75
Identifying HCV genotype 1 patients at risk of relapse. Eur J Gastroenterol Hepatol (2010) 0.75
Effect of high-dose vitamin C on hepatic cytochrome P450 3A4 activity. Pharmacotherapy (2005) 0.75
Influenza vaccination with 1/10th the full dose. N Engl J Med (2004) 0.75